GenMont Biotech Incorporation reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was TWD 368.55 million compared to TWD 427.93 million a year ago. Net income was TWD 56.98 million compared to TWD 113.13 million a year ago.

Basic earnings per share from continuing operations was TWD 0.66 compared to TWD 1.31 a year ago. Diluted earnings per share from continuing operations was TWD 0.66 compared to TWD 1.3 a year ago.